The above findings suggest that enhancing the NPR-C pathway may represent an attractive therapeutic strategy to reduce body wasting, increase the ability to tolerate higher HF therapeutic doses, and improve HF outcomes. The gene discussed is NPR3; the disease is hydrops fetalis.